Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gauging the Risks of Financing Convergence Start-Ups

This article was originally published in Start Up

Executive Summary

A handful of recent biotech-device company deals have highlighted the potential of drug-device convergence as natural extensions of the ever-popular repurposing and drug delivery models espoused by investors aiming to reduce the risks associated with drug discovery. Venture capitalists are eager to get in on the game, but drug and device hybrid business models are few and far between. True convergence start-ups remain thin on the ground, a fact VCs say reflects the additive nature of drug risk and device risk.

You may also be interested in...



Step-Ups in Convergence Plays

The rationale for drug-device convergence companies-combining the device sector's speed to market and relative lack of clinical risk with the biopharma sector's margins-may be gaining some traction as of late. Half of the eight device IPOs to close so far this year, in fact, are arguably convergence plays.

Step-Ups in Convergence Plays

The rationale for drug-device convergence companies-combining the device sector's speed to market and relative lack of clinical risk with the biopharma sector's margins-may be gaining some traction as of late. Half of the eight device IPOs to close so far this year, in fact, are arguably convergence plays.

Stem Cells: What's the Business Model?

The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel